|
CU22584A1
(es)
*
|
1995-11-17 |
1999-11-03 |
Centro Inmunologia Molecular |
Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
|
|
BR9710811A
(pt)
|
1996-05-22 |
1999-08-17 |
Novopharm Biotech Inc |
Fragmentos de liga-Æo de antigeno que detecta especificamente c-lulas cancerigenas nucleotideos que codificam os fragmentos e o seu uso para a profilaxia e detec-Æo de c-nceres
|
|
EP0909277B2
(en)
|
1996-06-07 |
2008-12-24 |
Poniard Pharmaceuticals, Inc. |
Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
|
|
EP0946727B1
(en)
*
|
1996-11-27 |
2007-01-24 |
Genentech, Inc. |
Antibody mutants
|
|
US6037454A
(en)
|
1996-11-27 |
2000-03-14 |
Genentech, Inc. |
Humanized anti-CD11a antibodies
|
|
EP0983303B1
(en)
*
|
1997-05-21 |
2006-03-08 |
Biovation Limited |
Method for the production of non-immunogenic proteins
|
|
US7115722B1
(en)
|
1997-05-22 |
2006-10-03 |
Viventia Biotech, Inc. |
Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
|
|
ES2221717T3
(es)
|
1997-12-08 |
2005-01-01 |
Emd Lexigen Research Center Corp. |
Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
|
|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
|
US6936249B1
(en)
|
1998-04-15 |
2005-08-30 |
Genencor International, Inc. |
Proteins producing an altered immunogenic response and methods of making and using the same
|
|
CN1318092C
(zh)
*
|
1998-04-15 |
2007-05-30 |
利思进药品公司 |
含有抗体-细胞因子融合蛋白和血管生成抑制剂的免疫治疗用组合物
|
|
US6835550B1
(en)
|
1998-04-15 |
2004-12-28 |
Genencor International, Inc. |
Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
|
|
US6838269B1
(en)
|
1998-04-15 |
2005-01-04 |
Genencor International, Inc. |
Proteins producing an altered immunogenic response and methods of making and using the same
|
|
AU776910B2
(en)
*
|
1998-12-08 |
2004-09-23 |
Merck Patent Gesellschaft Mit Beschrankter Haftung |
Modifying protein immunogenicity
|
|
US20050202538A1
(en)
*
|
1999-11-12 |
2005-09-15 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
|
CA2391080A1
(en)
|
1999-11-12 |
2001-05-25 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Erythropoietin forms with improved properties
|
|
CU22921A1
(es)
*
|
1999-11-16 |
2004-02-20 |
Centro Inmunologia Molecular |
Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales
|
|
JP5179689B2
(ja)
|
2000-02-11 |
2013-04-10 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗体ベース融合タンパク質の循環系内半減期の増強
|
|
CA2409361A1
(en)
*
|
2000-05-19 |
2001-11-22 |
Scancell Limited |
Humanised antibodies to the epidermal growth factor receptor
|
|
CZ2003214A3
(cs)
*
|
2000-06-29 |
2003-08-13 |
Merck Patent Gmbh |
Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu
|
|
CU22979A1
(es)
*
|
2000-12-08 |
2004-09-09 |
Centro Inmunologia Molecular |
Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
|
|
CN1491232A
(zh)
*
|
2001-02-06 |
2004-04-21 |
Ĭ��ר������˾ |
免疫原性减弱的经修饰肥胖蛋白
|
|
JP4279554B2
(ja)
*
|
2001-02-19 |
2009-06-17 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
T細胞エピトープの識別方法および低減された免疫原性を有する分子の製造方法
|
|
WO2002066058A1
(en)
*
|
2001-02-19 |
2002-08-29 |
Merck Patent Gmbh |
Modified anti-egfr antibodies with reduced immunogenicity
|
|
DK1366067T3
(da)
*
|
2001-03-07 |
2012-10-22 |
Merck Patent Gmbh |
Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
|
|
US6992174B2
(en)
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
|
CU23007A1
(es)
*
|
2001-04-06 |
2004-12-17 |
Ct De Inmunologia Molecular Ct De Inmunologia Mole |
Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
|
|
BR0209177A
(pt)
|
2001-05-03 |
2004-10-05 |
Merck Patent Gmbh |
Anticorpo especìfico a tumor recombinante e uso do mesmo
|
|
DK1392359T4
(da)
|
2001-05-11 |
2013-06-10 |
Ludwig Inst For Cancer Res Ltd |
Specifikke bindingsproteiner og deres anvendelser.
|
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
|
US20020197253A1
(en)
*
|
2001-05-22 |
2002-12-26 |
Cheek Dennis J. |
Compositions and methods for promoting or inhibiting NDPK
|
|
EP1395274A2
(en)
*
|
2001-05-22 |
2004-03-10 |
Duke University |
Compositions and methods for inhibiting metastasis
|
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
|
WO2003018749A2
(en)
|
2001-08-22 |
2003-03-06 |
Shengfeng Li |
Compositions and methods for generating antigen-binding units
|
|
US7175983B2
(en)
|
2001-11-02 |
2007-02-13 |
Abmaxis, Inc. |
Adapter-directed display systems
|
|
AU2002351957B2
(en)
*
|
2001-11-12 |
2009-09-03 |
Merck Patent Gmbh |
Modified anti-TNF alpha antibody
|
|
EP1454138B1
(en)
|
2001-12-04 |
2012-01-18 |
Merck Patent GmbH |
Immunocytokines with modulated selectivity
|
|
US20040067532A1
(en)
*
|
2002-08-12 |
2004-04-08 |
Genetastix Corporation |
High throughput generation and affinity maturation of humanized antibody
|
|
ATE471946T1
(de)
|
2002-12-17 |
2010-07-15 |
Merck Patent Gmbh |
Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
|
|
CU23403A1
(es)
|
2003-04-23 |
2009-08-04 |
Centro Inmunologia Molecular |
Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
|
|
EP1644416A4
(en)
*
|
2003-06-30 |
2007-08-29 |
Centocor Inc |
ANTI-TARGET AND GENETICALLY MODIFIED IMMUNOGLOBULIN-DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
|
|
EP1694706B1
(en)
*
|
2003-11-01 |
2012-04-04 |
Merck Patent GmbH |
Modified anti-cd52 antibody
|
|
EP1533617A1
(en)
*
|
2003-11-19 |
2005-05-25 |
RMF Dictagene S.A. |
Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
|
|
US7642341B2
(en)
|
2003-12-18 |
2010-01-05 |
Merck Serono S.A. |
Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
|
|
JP2007512846A
(ja)
*
|
2003-12-04 |
2007-05-24 |
ゼンコー・インコーポレイテッド |
増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
|
|
KR101163424B1
(ko)
|
2003-12-30 |
2012-07-13 |
메르크 파텐트 게엠베하 |
Il-7 융합 단백질
|
|
EP1699821B1
(en)
*
|
2003-12-31 |
2012-06-20 |
Merck Patent GmbH |
Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
|
|
CA2553883C
(en)
|
2004-01-22 |
2013-04-02 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Anti-cancer antibodies with reduced complement fixation
|
|
CA2555306A1
(en)
*
|
2004-02-06 |
2005-08-18 |
Nymox Corporation |
Humanized antibody
|
|
ZA200608572B
(en)
*
|
2004-04-16 |
2008-06-25 |
Genentech Inc |
Assay for antibodies
|
|
EP1797176A2
(en)
*
|
2004-09-09 |
2007-06-20 |
University of Washington |
All-trans-retinol : all-trans-13,14-dihydroretinol saturase and methods of its use
|
|
CN101072793B
(zh)
|
2004-12-09 |
2012-06-20 |
默克专利有限公司 |
具有降低的免疫原性的il-7变体
|
|
CA2596833C
(en)
*
|
2005-02-03 |
2016-04-12 |
Antitope Limited |
Human antibodies and proteins
|
|
EP1869192B1
(en)
*
|
2005-03-18 |
2016-01-20 |
MedImmune, LLC |
Framework-shuffling of antibodies
|
|
AU2006226192A1
(en)
|
2005-03-19 |
2006-09-28 |
Medical Research Council |
Improvements in or relating to treatment and prevention of viral infections
|
|
PE20070374A1
(es)
*
|
2005-07-08 |
2007-05-12 |
Pfizer Ltd |
ANTICUERPOS ANTI-MAdCAM
|
|
JP2009502195A
(ja)
*
|
2005-08-04 |
2009-01-29 |
セントカー・インコーポレーテツド |
抗TNFα抗体および使用方法
|
|
US20070104689A1
(en)
*
|
2005-09-27 |
2007-05-10 |
Merck Patent Gmbh |
Compositions and methods for treating tumors presenting survivin antigens
|
|
JPWO2007049770A1
(ja)
|
2005-10-28 |
2009-04-30 |
明治製菓株式会社 |
緑膿菌の外膜タンパク質pa5158
|
|
AU2006332155B2
(en)
*
|
2005-12-30 |
2013-01-10 |
Cancer Research Technology Limited |
Anti-CD19 antibodies with reduced immunogenicity
|
|
KR20080113239A
(ko)
|
2006-03-30 |
2008-12-29 |
메이지 세이카 가부시키가이샤 |
녹농균의 외막 단백질 pa0427
|
|
DK2038306T3
(en)
|
2006-06-30 |
2015-03-09 |
Novo Nordisk As |
ANTI-NKG2A ANTIBODIES AND APPLICATIONS THEREOF
|
|
AU2007301599B2
(en)
*
|
2006-09-28 |
2013-01-10 |
Merck Serono S.A. |
Junctional Adhesion Molecule-C (JAM-C) binding compounds and methods of their use
|
|
MY154819A
(en)
|
2006-12-26 |
2015-07-31 |
Centro Inmunologia Molecular |
Pharmaceutical compositions with capacity to induce adoptosis in tumor cells for the diagnosis and treatment of the b-cell chroniclymphocytic leukemia
|
|
NZ578635A
(en)
*
|
2006-12-26 |
2012-03-30 |
Ct De Inmunolgia Molecular |
Pharmaceutical composition, comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis
|
|
US9090693B2
(en)
|
2007-01-25 |
2015-07-28 |
Dana-Farber Cancer Institute |
Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
|
|
JP5618549B2
(ja)
|
2007-03-15 |
2014-11-05 |
ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド |
Egfr抗体及びsrc阻害剤を用いる治療方法及び関連製剤
|
|
JP5532486B2
(ja)
|
2007-08-14 |
2014-06-25 |
ルードヴィッヒ インスティテュート フォー キャンサー リサーチ |
Egf受容体を標的とするモノクローナル抗体175ならびにその誘導体および用途
|
|
WO2009036379A2
(en)
|
2007-09-14 |
2009-03-19 |
Adimab, Inc. |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
US8877688B2
(en)
*
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
US12529164B2
(en)
|
2007-09-14 |
2026-01-20 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
US20100291070A1
(en)
|
2007-12-25 |
2010-11-18 |
Meiji Seika Kaisha, Ltd. |
Type iii secretion system component protein pa1698 of pseudomonas aeruginosa
|
|
MX2010007935A
(es)
|
2008-01-24 |
2010-08-23 |
Novo Nordisk As |
Anticuerpo monoclonal humanizado anti-nkg2a humano.
|
|
PT2993186T
(pt)
*
|
2008-03-14 |
2019-11-29 |
Biocon Ltd |
Anticorpo monoclonal e um método do mesmo
|
|
JPWO2009119794A1
(ja)
|
2008-03-27 |
2011-07-28 |
タカラバイオ株式会社 |
感染症予防、治療剤
|
|
US8420092B2
(en)
|
2009-03-19 |
2013-04-16 |
Ben-Gurion University Of The Negev Research And Development Authority |
Method of treating diabetes by administering an anti-NKp46 antibody
|
|
WO2010125566A2
(en)
|
2009-04-27 |
2010-11-04 |
Technion Research And Development Foundation Ltd. |
Markers for cancer detection
|
|
US8859736B2
(en)
|
2010-02-19 |
2014-10-14 |
The Board Of Regents Of The University Of Oklahoma |
Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof
|
|
US9485812B2
(en)
|
2010-07-08 |
2016-11-01 |
Honda Motor Co., Ltd. |
High frequency heating coil
|
|
US9675693B2
(en)
|
2010-09-30 |
2017-06-13 |
Riken |
Methods and drugs targeting Eva1 or Ceacam1 gene expression for treatment and diagnosing of glioma
|
|
EP3222635A1
(en)
|
2010-12-21 |
2017-09-27 |
Selexys Pharmaceuticals Corporation |
Anti-p-selectin antibodies and methods of their use and identification
|
|
WO2012090939A1
(ja)
|
2010-12-27 |
2012-07-05 |
国立大学法人名古屋大学 |
受容体型チロシンキナーゼが仲介する癌細胞の生存促進性シグナルを抑制する方法
|
|
US9555108B2
(en)
|
2011-03-24 |
2017-01-31 |
Texas Tech University System |
TCR mimic antibodies as vascular targeting tools
|
|
CA2835094C
(en)
*
|
2011-05-06 |
2020-12-22 |
David Gearing |
Anti-nerve growth factor antibodies and methods of preparing and using the same
|
|
ES2748577T3
(es)
|
2011-05-19 |
2020-03-17 |
Univ Michigan Regents |
Agentes de fijación de la integrina alfa-2 y uso de los mismos para inhibir la proliferación de las células de cáncer
|
|
EP2743699A4
(en)
|
2011-08-12 |
2015-04-08 |
Nat Inst Infectious Diseases |
METHOD FOR TESTING, PREVENTING AND TREATING INFECTIOUS DISEASE ASPERGILLUS FUMIGATUS AND COMPOSITION
|
|
CA2858806A1
(en)
|
2011-12-23 |
2013-06-27 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
|
WO2013140393A1
(en)
|
2012-03-21 |
2013-09-26 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Peptides derived from the d1 - domain of nkp46
|
|
US9416189B2
(en)
|
2012-05-11 |
2016-08-16 |
Microbial Chemistry Research Foundation |
Anti-CXADR antibody
|
|
EP2872894B1
(en)
|
2012-07-13 |
2019-04-17 |
Innate Pharma |
Screening of conjugated antibodies
|
|
AU2013297478B2
(en)
|
2012-07-30 |
2018-12-20 |
Medical & Biological Laboratories Co., Ltd. |
Monoclonal antibody against human midkine
|
|
WO2014036562A2
(en)
|
2012-08-31 |
2014-03-06 |
University Of Virginia Patent Foundation |
Target peptides for immunotherapy and diagnostics
|
|
HK1212236A1
(en)
|
2012-09-05 |
2016-06-10 |
University Of Virginia Patent Foundation |
Target peptides for colorectal cancer therapy and diagnostics
|
|
EP2896291B1
(en)
|
2012-09-13 |
2019-03-20 |
Chugai Seiyaku Kabushiki Kaisha |
Gene knock-in non-human animal
|
|
EP2916872B1
(en)
|
2012-11-09 |
2019-02-27 |
Innate Pharma |
Recognition tags for tgase-mediated conjugation
|
|
WO2014093855A1
(en)
|
2012-12-13 |
2014-06-19 |
University Of Virginia Patent Foundation |
Target peptides for ovarian cancer therapy and diagnostics
|
|
WO2014123227A1
(ja)
|
2013-02-08 |
2014-08-14 |
株式会社医学生物学研究所 |
ヒトnrg1タンパク質に対する抗体
|
|
EP3339327A3
(en)
|
2013-02-28 |
2018-09-19 |
National Cancer Center |
Antibody against insoluble fibrin
|
|
US10611824B2
(en)
|
2013-03-15 |
2020-04-07 |
Innate Pharma |
Solid phase TGase-mediated conjugation of antibodies
|
|
WO2014174596A1
(ja)
|
2013-04-23 |
2014-10-30 |
株式会社医学生物学研究所 |
ヘパリン結合上皮増殖因子様増殖因子に対する機能性モノクローナル抗体
|
|
WO2014202773A1
(en)
|
2013-06-20 |
2014-12-24 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
|
KR20160042871A
(ko)
|
2013-06-21 |
2016-04-20 |
이나뜨 파르마, 에스.아. |
폴리펩티드의 효소적 콘쥬게이션
|
|
US10189899B2
(en)
|
2013-07-23 |
2019-01-29 |
Biocon Limited |
Use of a CD6 binding partner and method based thereon
|
|
WO2015068781A1
(ja)
|
2013-11-06 |
2015-05-14 |
国立大学法人大阪大学 |
インフルエンザウイルスa型のグループ1に対して広域な中和活性を有する抗体
|
|
EP3221349B1
(en)
|
2014-11-19 |
2020-11-04 |
Axon Neuroscience SE |
Humanized tau antibodies in alzheimer's disease
|
|
EP3331544A4
(en)
|
2015-08-07 |
2019-03-27 |
University Of Virginia Patent Foundation |
IDENTIFICATION OF CLASS 1 MHC ASSOCIATED GLYCOPEPTIDES AS OBJECTIVES TO CANCER IMMUNOTHERAPY
|
|
WO2017201731A1
(en)
|
2016-05-27 |
2017-11-30 |
Beijing Vdjbio Co., Ltd. |
Antibodies, composition and kits comprising same, and methods of use thereof
|
|
CN106632681B
(zh)
*
|
2016-10-11 |
2017-11-14 |
北京东方百泰生物科技有限公司 |
抗egfr和抗cd3双特异抗体及其应用
|
|
KR102514528B1
(ko)
|
2016-10-21 |
2023-03-27 |
바이오콘 리미티드 |
루푸스 치료를 위한 단일클론항체 및 이의 치료방법
|
|
KR102607101B1
(ko)
|
2017-01-26 |
2023-11-29 |
제트엘아이피 홀딩 리미티드 |
Cd47 항원 결합 유닛 및 그것의 사용
|
|
CN111201030B
(zh)
|
2017-07-25 |
2024-11-01 |
真和制药有限公司 |
通过阻断tim-3和其配体的相互作用治疗癌症
|
|
WO2019169015A1
(en)
|
2018-02-27 |
2019-09-06 |
Equillium, Inc. |
Anti cd6 antibodies for treating severe asthma
|
|
AU2019244481A1
(en)
|
2018-03-28 |
2020-10-01 |
Axon Neuroscience Se |
Antibody-based methods of detecting and treating Alzheimer's disease
|
|
US20210355199A1
(en)
|
2018-06-28 |
2021-11-18 |
University Of Virginia Patent Foundation |
Compositions and methods for detecting and regulating fibronectin-integrin interaction and signaling
|
|
CN112512584A
(zh)
|
2018-07-27 |
2021-03-16 |
国立大学法人大阪大学 |
用于抑制衰老、预防、改善或治疗衰老相关疾病或症状、或者延长寿命的组合物
|
|
EP3854875B1
(en)
|
2018-09-21 |
2026-01-14 |
Institute of Science Tokyo |
Human monoclonal antibody binding specifically to human hmgb1, and pharmaceutical composition for treating or preventing alzheimer's disease containing said human monoclonal antibody
|
|
CA3115660A1
(en)
|
2018-10-12 |
2020-04-16 |
Hassan JUMAA-WEINACHT |
Monoclonal antibody composition for treatment of philadelphia chromosome positive acute lymphoblastic leukemia
|
|
EP4219550A1
(en)
|
2018-11-02 |
2023-08-02 |
Oklahoma Medical Research Foundation |
Monoclonal antibodies to eltd1 and uses thereof
|
|
KR20210124308A
(ko)
|
2019-01-30 |
2021-10-14 |
트루바인딩 아이엔씨. |
항-gal3 항체 및 이의 용도
|
|
WO2020176682A1
(en)
|
2019-02-26 |
2020-09-03 |
Equillium, Inc. |
Anti-cd6 antibody compositions and methods for treating lupus
|
|
CN115279789A
(zh)
|
2019-12-06 |
2022-11-01 |
真和制药有限公司 |
破坏gal3和胰岛素受体或整联蛋白的相互作用的抗体及其使用方法
|
|
US12662535B2
(en)
|
2020-01-17 |
2026-06-23 |
Immunelogic Therapeutics, Inc. |
Pro-antibody that reduces off-target toxicity
|
|
JPWO2021200131A1
(es)
|
2020-03-30 |
2021-10-07 |
|
|
|
MX2022014786A
(es)
|
2020-05-26 |
2023-01-16 |
Truebinding Inc |
Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
|
|
US20240025985A1
(en)
|
2020-12-09 |
2024-01-25 |
National University Corporation Tokyo Medical And Dental University |
Agent for Preventing or Treating Frontotemporal Lobar Degeneration
|
|
JP2024526764A
(ja)
|
2021-07-13 |
2024-07-19 |
トゥルーバインディング,インコーポレイテッド |
タンパク質凝集を防止する方法
|
|
US20230279120A1
(en)
|
2021-11-09 |
2023-09-07 |
Truebinding, Inc. |
Methods of treating or inhibiting cardiovascular diseases
|
|
TW202440647A
(zh)
|
2021-11-19 |
2024-10-16 |
英商米羅比奧有限公司 |
經工程改造之pd-1抗體及其用途
|
|
CN119213128A
(zh)
|
2022-03-09 |
2024-12-27 |
株式会社丘阿德 |
与Eva1蛋白质结合的人源化抗体或其功能性片段、抗体药物缀合物和嵌合抗原受体
|
|
WO2023196866A1
(en)
|
2022-04-06 |
2023-10-12 |
Mirobio Limited |
Engineered cd200r antibodies and uses thereof
|
|
JPWO2023238869A1
(es)
|
2022-06-07 |
2023-12-14 |
|
|
|
CN120456922A
(zh)
|
2022-11-25 |
2025-08-08 |
国立大学法人大阪大学 |
针对血液癌的抗体
|
|
WO2025036848A1
(en)
|
2023-08-11 |
2025-02-20 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Anti-muc16 antibodies and uses thereof
|
|
AR134368A1
(es)
|
2023-11-17 |
2026-01-07 |
Wuxi Biologics Ireland Ltd |
Anticuerpos anti-muc16 y usos de los mismos
|